Richard Keenan, PhD, has over twenty years experience in medicinal chemistry research, contributing directly to the discovery of numerous clinical development compounds from a variety of therapeutic areas, including two marketed drugs: the Angiotensin Receptor blocker Teveten and the TPO receptor agonist Promacta. At GlaxoSmithKline, he served as VP of Drug Discovery and was one of the founding members of the Center of Excellence for External Drug Discovery (CEEDD).